Flower City Capital Acquires Shares of 3,000 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Flower City Capital acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the fourth quarter, Holdings Channel reports. The fund acquired 3,000 shares of the company’s stock, valued at approximately $254,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in Axsome Therapeutics in the second quarter valued at about $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth $47,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after buying an additional 318 shares in the last quarter. Moors & Cabot Inc. acquired a new stake in Axsome Therapeutics in the 3rd quarter valued at about $200,000. Finally, Whalen Wealth Management Inc. purchased a new position in Axsome Therapeutics during the 3rd quarter valued at about $236,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AXSM has been the topic of several recent research reports. Mizuho reduced their price target on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, December 31st. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Royal Bank of Canada upped their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Finally, Robert W. Baird upped their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $130.69.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $91.93 on Monday. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The company has a market cap of $4.45 billion, a PE ratio of -14.08 and a beta of 1.04. The company’s fifty day simple moving average is $92.27 and its 200-day simple moving average is $89.53. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the firm posted ($1.32) earnings per share. As a group, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -4.61 EPS for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.